25907-38-4

Usage

Uses

Used in Food and Beverage Industry:
Ethyl 3-oxo-4-(phenylthio)butanoate is used as a flavoring agent for its fruity and floral aroma, enhancing the taste and scent profiles of various food and beverage products.
Used in Perfume and Fragrance Industry:
Ethyl 3-oxo-4-(phenylthio)butanoate is utilized in the production of perfumes and fragrances, where its aromatic properties contribute to creating complex and appealing scents.
Used in Pharmaceutical Industry:
Ethyl 3-oxo-4-(phenylthio)butanoate has potential applications in pharmaceuticals, although the specific uses are not detailed in the provided materials. Its chemical structure may offer opportunities for development in medicinal chemistry.
Used in Agrochemical Industry:
Similarly, the compound has potential applications in agrochemicals, although the exact uses are not specified. Its properties might be harnessed for various purposes in agricultural chemistry, such as in the development of pesticides or other related products.
Ethyl 3-oxo-4-(phenylthio)butanoate is typically stored and handled following standard chemical safety protocols to ensure safe usage and handling in these industries.

Upstream product

• 141-97-9 ethyl acetoacetate 
• 882-33-7 diphenyldisulfane 
• 108-98-5 thiophenol 
• 7031-27-8 (phenylthio)acetic acid chloride 
• 6148-64-7 ethyl potassium malonate 
• 638-07-3 ethyl (2-chloroaceto)acetate 

Downstream Products

• 71027-69-5 2,4-Dihydroxy-6-phenylsulfanylmethyl-benzoic acid ethyl ester 
• 64089-24-3 2,6-dimethyl-3,5-dicyano-4-(3-pyridyl)-1,4-dihydropyridine 
• 134968-73-3 5'-Cyano-6'-methyl-2'-phenylsulfanylmethyl-1',4'-dihydro-[3,4']bipyridinyl-3'-carboxylic acid ethyl ester 
• 107975-10-0 2'-Methyl-6'-phenylsulfanylmethyl-1',4'-dihydro-[3,4']bipyridinyl-3',5'-dicarboxylic acid diethyl ester 
• 98-01-1 furfural 
• 64089-27-6 4-(2-furyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonitrile 
• 99698-34-7 3-(phenylthiomethyl)isoxazol-5(4H)-one 
• 97138-17-5 ethyl 3-oxo-4-(phenylsulfonyl)butanoate 
• 134968-39-1 (3R,4R)-5-Cyano-4-(2-difluoromethoxy-phenyl)-6-methyl-2-[1-phenylsulfanyl-meth-(Z)-ylidene]-1,2,3,4-tetrahydro-pyridine-3-carboxylic acid ethyl ester 
• 107974-85-6 5-Cyano-6-methyl-2-phenylsulfanylmethyl-4-(2-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid ethyl ester 
• 107975-75-7 ethyl 5-cyano-1,2,3,4-tetrahydro-6-methyl-2-<(phenylthio)methylene>-4-<(2-trifluoromethyl)phenyl>-3-pyridinecarboxylate 
• 35929-86-3 2,6-dimethyl-4-phenyl-1,4-dihydro-pyridine-3,5-dicarbonitrile 
• 107974-99-2 5-Cyano-6-methyl-4-phenyl-2-phenylsulfanylmethyl-1,4-dihydro-pyridine-3-carboxylic acid ethyl ester 
• 134968-41-5 (3S,4S)-5-Cyano-4-cyclohexyl-6-methyl-2-[1-phenylsulfanyl-meth-(Z)-ylidene]-1,2,3,4-tetrahydro-pyridine-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds

Targeting the protein-protein interaction (PPI) between nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) is a potential therapeutic strategy to control diseases involving oxidative stress. Here, six classes of known small-molecule Keap1-Nrf2 PPI inhibitors were dissected into 77 fragments in a fragment-based deconstruction reconstruction (FBDR) study and tested in four orthogonal assays. This gave 17 fragment hits of which six were shown by X-ray crystallography to bind in the Keap1 Kelch binding pocket. Two hits were merged into compound 8 with a 220-380-fold stronger affinity (Ki = 16 μM) relative to the parent fragments. Systematic optimization resulted in several novel analogues with Ki values of 0.04-0.5 μM, binding modes determined by X-ray crystallography, and enhanced microsomal stability. This demonstrates how FBDR can be used to find new fragment hits, elucidate important ligand-protein interactions, and identify new potent inhibitors of the Keap1-Nrf2 PPI.

COMPOUNDS AS RAS INHIBITORS AND USE THEREOF

A compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

3-heterocycle substituted quinoline derivatives as well as preparation method and applications thereof

The invention relates to new quinoline derivatives shown in a general formula I and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and wherein substituent R1, R2, R3 and n contain meanings shown in the specification. The invention also relates to an enhanced effect of the compounds shown in formula I for inhibiting DNA duplication of HBV, and also relates to applications of the compounds and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof to preparation of medicaments for treating diseases due to infection of HBV, and especially relates to applications of medicaments for treating and/or preventing viral hepatitis B.

An efficient five-component synthesis of thioether containing dihydropyrano[2,3-c]pyrazoles: a green domino strategy

An efficient route for the synthesis of novel thioether containing dihydropyrano[2,3-c]pyrazoles has been accomplished via a solvent-free, catalyst-free, one-pot, five component domino strategy. This synthetic approach offers several advantages such as an easy work-up, no need for purification techniques and a short reaction time with good atom economy and high yields of the products (81-86%).

Synthesis and Anti-Hepatitis B Virus Evaluation of 7-Methoxy-3-heterocyclic quinolin-6-ols

A series of novel 7-methoxy-3-heterocyclic quinolin-6-ol derivatives were synthesized and evaluated for their anti-hepatitis B virus (HBV) activities and cytotoxicities in the HepG2.2.15 cell line. Five compounds, 14a, 15c, 15e, 16b, and 16f, displayed ex

Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease currently without a cure. Mutations in copper/zinc superoxide dismutase 1 (SOD1) have been implicated in the pathophysiology of this disease. Using a high-throughput screening assa

Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro

A series of ethyl 1H-indole-3-carboxylates 9a1- 6 and 9b1-2 were prepared and evaluated in Huh-7.5 cells. Most of the compounds exhibited anti-hepatitis C virus (HCV) activities at low concentration. The selectivity indices of inhibition on entry and replication of compounds 9a2 (>10; >16.7) and 9b1 (>6.25; >16.7) were higher than those of the other evaluated compounds, including the lead compound Arbidol (ARB, 6; 15). Moreover, the selective index of inhibition on entry of compound 9a3 (>6.25) was higher than that of ARB (6). Of these three initial hits, compound 9a2 was the most potent.

A facile synthesis and discovery of highly functionalized tetrahydropyridines and pyridines as antimycobacterial agents

The four-component reaction of ethyl-3-oxo-4-(arylsulfanyl)butanoate, substituted aromatic aldehydes and ammonium acetate afforded novel ethyl 4-hydroxy-2,6-diaryl-5-(arylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylates. These tetrahydro-pyridine ester

Synthesis of functionalized diaryl sulfides based on regioselective one-pot cyclizations of 1,3-bis(trimethylsilyloxy)-1,3-butadienes

Functionalized diaryl sulfides were prepared based on one-pot cyclizations of 1,3-bis(trimethylsilyloxy)-1,3-butadienes.

Synthesis and anti-HBV activities evaluation of new ethyl 8-imidazolylmethyl-7-hydroxyquinoline-3-carboxylate derivatives in vitro

Some new ethyl 8-imidazolylmethyl-7-hydroxyquinoline-3-carboxylate derivatives have been synthesized and evaluated for their anti-hepatitis B virus (HBV) activities and cytotoxicities in HepG2.2.15 cells stable transfection with HBV. Compounds 13a, 11b, 11c, 12c, 13c, 11g, and 12g inhibited the expression of the viral antigens HBsAg or HBeAg in a low concentration, of which 11c (IC50 = 12.6 μM, SI = 12.4), 12c (IC50 = 3.5 μM, SI = 37.9), and 12g (IC50 = 2.6 μM, SI = 61.6) showed more active abilities to inhibit the replication of HBV DNA than the positive control lamivudine (3TC, IC50 = 343.2 μM, SI = 7.0).